Kansas City Business Journal - Lee’s Summit’s Viracor Eurofins develops at-home Covid-19 test kit
Lee's Summit-based Viracor Eurofins has developed an at-home Covid-19 test kit that now has received emergency-use authorization from the Food and Drug Administration.
Viracor's nasal test is less invasive than others on the market, and the swab is similar to a Q-tip, Viracor President Dr. Michelle Altrich told the Kansas City Business Journal.
The Kansas City Star - Viracor Launches COVID-19 At-Home Test Kit
The at-home test, created by Viracor Eurofins, can be ordered online for $89. Viracor says patients will get results within 24 hours — no more than 48 hours — from the time it receives the sample.
You collect the sample yourself from your nose, rubbing a swab inside both nostrils. The test’s developers say it’s more comfortable than that COVID-19 test you might have had at the doctor’s office or community testing site.
Mass Device - FDA Issues EUA for Viracor Eurofins' At-Home COVID-19 Test
Luxembourg-based Eurofins’ at-home nasal PCR test is touted as a minimally invasive and quick option that offers results via email within 24 hours of sample receipt. The test is available through Eurofins’ direct-to-consumer company, EmpowerDX, and is offered online for $89.
The test was developed based on Eurofins’ previously authorized SARS-CoV-2 RT-PCR assay, which received EUA back in March. The company has ramped up its U.S. testing capacity to over 500,000 samples per week with a turnaround time averaging less than 18 hours.
Eurofins U.S. Clinical Diagnostics Network Receives EUA Approval of At Home COVID-19 Test
Viracor has received EUA from the U.S. Food and Drug Administration (FDA) for their At-Home COVID-19 Nasal PCR Test. The EUA authorized self-collection kit gives consumers a minimally invasive, convenient and quick option to test from the comfort of their home. Results are provided via email within 24 hours of sample receipt.
Invicta FC Partners with Global Laboratory Testing Provider, Eurofins, to Bolster Athlete Safety During COVID-19 Pandemic
Since the start of the COVID-19 pandemic, all Invicta FC events have featured testing for athletes, corners, Invicta FC staff and commission officials. Now, leveraging Eurofins’ SAFER@WORK™ protocols, the world’s leading combat sports organization for women has ensured that future events will continue to be a safe environment for all participants.
Viracor Eurofins Collaborates with Northwestern University Comprehensive Transplant Center on Specialized Kidney Transplant Diagnostic
Viracor Eurofins announces research collaboration with the Northwestern University Comprehensive Transplant Center, a leader in solid organ transplantation medicine in North America through high impact research and its clinical training programs. This research collaboration will further verify the novel test obtained through Eurofins’ recent acquisition of Transplant Genomics Inc. (“TGI”), and its blood gene expression test, TruGraf®.
Eurofins U.S. Clinical Diagnostics Network Announces Launch of Highly Accurate, Cost Effective, COVID-19 Pooled PCR Test
Eurofins U.S. Clinical Diagnostics announced the launch date of its pooled PCR test to detect SARS-CoV-2 and significantly reduce the price per PCR test for clients. Pooling tests, historically used in blood banks, can now be used by the myriad of industries seeking a highly accurate and cost-effective means to conduct COVID-19 testing.
TGI and Viracor Announce Transplant Advisory Board, to focus on trends and innovations in transplant diagnostics
Viracor and Transplant Genomics Inc (TGI) announce the formation of the Eurofins Transplant Medical and Scientific Advisory Board, employing diverse expertise and experience in transplantation and technology development to enhance the clinical value of diagnostics throughout the transplant community.